ClinicalTrials.gg
Not yet recruitingNCT07444554Updated Oct 14, 2026

High-Velocity Resistance Training for Brain Blood Flow and Cognitive Function in Older Adults

An interventional study of High-Velocity Resistance Training in At Risk for AD-dementia, With Subjective Cognitive Decline and At Risk for Cognitive Decline, sponsored by University of Illinois at Chicago. Not yet recruiting. Open to participants aged 60 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by University of Illinois at Chicago · Not applicable, Interventional, and Treatment

How we know

Updated Oct 14, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years to 79 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether a 12-week high-velocity resistance training program can improve brain blood flow and thinking skills in adults ages 60 to 79 who are at higher risk for Alzheimer's disease and related dementias. Researchers want to understand whether this type of exercise can improve how well the brain regulates blood flow during mental and physical tasks and whether those changes are linked to improvements in thinking ability. The main questions this study aims to answer are whether high-velocity resistance training improves thinking skills such as executive function and processing speed, and whether it improves how blood flow in the brain responds during cognitive testing, changes in blood pressure, and controlled breathing tasks. Participants will complete two study visits at the University of Illinois Chicago, one before the program begins and one after 12 weeks. During these visits, researchers will measure strength, muscle power, and thinking skills. Participants will also complete non-invasive testing to measure blood flow in the brain using ultrasound. During some tasks, participants will walk on a treadmill at a comfortable pace while completing thinking tests. They will wear small sensors to measure heart rate, blood pressure, and breathing. After the first visit, participants will be randomly assigned, like flipping a coin, to one of two groups. One group will take part in supervised resistance training three times per week for 12 weeks at the University of Illinois Chicago. Each session will last about 60 minutes and will be supervised by trained exercise professionals. The other group will continue their usual daily activities for 12 weeks and then return for follow-up testing. Participants in the comparison group will be offered the exercise program after they complete the final study visit. Researchers hope this study will improve understanding of how structured exercise may support brain health in older adults at risk for dementia and help guide future prevention strategies.

Read the detailed description

This study is a single-site, randomized, parallel-group clinical trial designed to evaluate both behavioral efficacy and mechanistic target engagement of high-velocity resistance training (HVRT) in older adults at elevated risk for Alzheimer's disease and related dementias (AD/ADRD). The trial is structured as an early-stage efficacy study consistent with a Stage IIA framework, with emphasis on testing a hypothesized physiological mechanism linking exercise to cognitive outcomes. A growing body of research suggests that vascular dysfunction may contribute to cognitive decline and dementia risk. Altered cerebrovascular regulation, including impaired neurovascular coupling, reduced dynamic cerebral autoregulation, and diminished cerebrovascular reactivity to carbon dioxide, has been observed in older adults and in individuals with vascular risk factors. These physiological impairments may limit the brain's ability to appropriately regulate blood flow during cognitive and physical demands. Exercise interventions may improve vascular function; however, the specific effects of high-velocity resistance training on cerebrovascular regulatory mechanisms and their relationship to cognitive performance remain insufficiently characterized. High-velocity resistance training emphasizes rapid concentric muscle actions performed against moderate external loads. This training approach is designed to improve neuromuscular power, which declines with aging and is strongly associated with functional mobility. HVRT may provide distinct hemodynamic and neurovascular stimuli compared to traditional resistance training due to the speed of contraction and associated pressor responses. This study will test whether a 12-week supervised HVRT intervention produces measurable improvements in executive function, processing speed, and motor-cognitive performance, and whether such improvements are associated with changes in cerebrovascular regulation. Participants will be randomized in a 1:1 ratio to either the HVRT intervention or a waitlist control condition. The intervention consists of three supervised sessions per week for 12 weeks, using progressive loading phases spanning approximately 40 to 80 percent of one-repetition maximum. All training sessions are conducted in person under the supervision of trained exercise professionals following standardized operating procedures. The waitlist control group will maintain usual activities during the 12-week period and will be offered the exercise program after completing post-intervention testing. Cognitive and motor-cognitive performance will be assessed under both single-task (seated) and dual-task (treadmill walking) conditions to evaluate cognitive function under varying levels of physiological demand. Dual-task paradigms are included to probe real-world motor-cognitive integration and to assess whether exercise-related adaptations extend to functionally relevant conditions. Cerebrovascular regulation will be assessed non-invasively using transcranial Doppler ultrasound to measure cerebral artery blood flow velocity. Continuous electrocardiography, beat-to-beat blood pressure monitoring, and end-tidal carbon dioxide measurement will be recorded concurrently to permit integrated physiological modeling. Neurovascular coupling will be evaluated as the change in cerebral blood flow velocity during cognitive activation. Dynamic cerebral autoregulation will be assessed using oscillatory lower-body negative pressure protocols to induce controlled blood pressure fluctuations. Cerebrovascular reactivity will be assessed using a standardized hypercapnic rebreathing procedure to quantify the cerebral blood flow response to elevated carbon dioxide levels. Primary analyses will examine group-by-time interaction effects on cognitive performance. Secondary analyses will evaluate changes in neurovascular coupling, dynamic cerebral autoregulation, and cerebrovascular reactivity. Exploratory analyses will estimate whether changes in cerebrovascular regulation statistically mediate intervention-related improvements in cognitive outcomes and whether biological sex moderates these associations. These mechanistic analyses are intended to inform the design of future fully powered efficacy trials. This study will contribute to understanding whether a scalable, supervised resistance training intervention can engage cerebrovascular mechanisms linked to cognitive performance in older adults at elevated dementia risk. Findings may inform the development of targeted exercise-based strategies to support brain health in aging populations.

02

Conditions studied

  • At Risk for AD-dementia, With Subjective Cognitive Decline
  • At Risk for Cognitive Decline

Browse trials for

Keywords

  • High velocity resistance training
  • Resistance training
  • Power training
  • Cerebrovascular regulation
  • Cerebrovascular function
  • Cerebrovascular impairment
  • Neurovascular coupling
  • Dynamic cerebral autoregulation
  • Cerebrovascular reactivity
  • Transcranial Doppler ultrasound
  • Executive function
  • Processing speed
  • Dual task walking
  • Motor cognitive performance
  • Prevention
  • Older adults
  • Alzheimer's disease
  • Alzheimer's disease risk
  • Alzheimer's disease and related dementia
  • Vascular cognitive impairment
03

In context

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's planned enrollment of 60 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

University of Illinois at Chicago is the lead sponsor of 496 studies on the registry; 115 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 60 to 79 years
  • Able to walk on a treadmill at a comfortable, self-selected pace for at least 30 minutes with short breaks
  • Has at least one vascular risk factor (such as high blood pressure or high cholesterol)
  • Has a first-degree family history of dementia or self-reported concerns about memory or thinking
  • Fluent in English
  • Willing and able to provide written
  • Cleared to participate in supervised resistance training based on physical activity screening and, if required, physician clearance

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of Alzheimer disease, other dementia, stroke, Parkinson disease, multiple sclerosis, or another major neurological disorder
  • Unstable cardiovascular disease (such as recent heart attack, unstable chest pain, or uncontrolled abnormal heart rhythm)
  • Uncontrolled high blood pressure
  • Major psychiatric illness that would interfere with participation
  • Medical condition that makes moderate-to-high intensity resistance training unsafe
  • Current participation in structured high-intensity resistance training
  • Any medical condition that, in the opinion of the study investigator, would increase risk during participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    High-Velocity Resistance Training

    Participants in this arm will complete a 12-week supervised high-velocity resistance training program. Sessions will occur three times per week and last approximately 60 minutes each. Exercises will include multi-joint upper- and lower-body movements performed at moderate loads, progressing from approximately 40 to 80 percent of one-repetition maximum over three phases. All sessions will be conducted in person and supervised by trained exercise professionals. Participants will also complete baseline and post-intervention cognitive and cerebrovascular assessments.

    Behavioral: High-Velocity Resistance Training

  • No intervention
    Waitlist Control (Usual Activity)

    Participants in this arm will maintain their usual daily activities for 12 weeks and will not receive structured exercise during the study period. They will complete the same baseline and post-intervention cognitive and cerebrovascular assessments as the intervention group. After completing post-intervention testing, participants will be offered the supervised resistance training program.

Interventions

  • BehavioralHigh-Velocity Resistance Training

    This intervention consists of supervised resistance training emphasizing rapid concentric muscle contractions performed against moderate external loads. Participants will train three times per week for 12 weeks, with each session lasting approximately 60 minutes. The program includes progressive loading across three phases, beginning at approximately 40 to 50 percent of one-repetition maximum, progressing to 50 to 65 percent, and then to 65 to 80 percent. Exercises target major upper- and lower-body muscle groups using resistance equipment. All sessions are conducted in person under supervision of trained exercise professionals to ensure proper technique, safety monitoring, and progression.

    Also known as: Power Training, Resistance Training

06

What researchers measure

Primary outcomes

  1. Change in Executive Function Standard Score

    Executive function will be assessed using standardized computerized cognitive tests from the National Institutes of Health Toolbox. Participants will first complete the tests in a seated single-task condition, followed by completion of the same tests during treadmill walking (dual-task condition). Age-adjusted standard scores will be used (mean = 100, standard deviation = 15; higher scores indicate better performance). Dual-task cost will be calculated as the percent difference between dual-task and seated performance using the formula: \[(dual-task standard score - single-task standard score) / single-task standard score\] × 100. The primary metric is the change in executive function dual-task cost (%) from baseline to 12 weeks.

    Time frame: Baseline and 12 weeks

  2. Change in Processing Speed Standard Score

    Processing speed will be assessed using standardized computerized cognitive tests from the National Institutes of Health Toolbox. Participants will first complete the tests in a seated single-task condition, followed by completion of the same tests during treadmill walking (dual-task condition). Age-adjusted standard scores will be used (mean = 100, standard deviation = 15; higher scores indicate better performance). Dual-task cost will be calculated as the percent difference between dual-task and seated performance using the formula: \[(dual-task standard score - single-task standard score) / single-task standard score\] × 100. The primary metric is the change in processing speed dual-task cost (%) from baseline to 12 weeks.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change in Neurovascular Coupling

    Neurovascular coupling will be assessed using transcranial Doppler ultrasound to measure cerebral artery blood flow velocity (cm/s). Neurovascular coupling is defined as the change in cerebral blood flow velocity during cognitive activation compared to resting baseline. The primary metric will be the task-related change in cerebral blood flow velocity expressed as absolute change (cm/s) and/or percent change (%). Greater task-related increases indicate improved neurovascular responsiveness.

    Time frame: Baseline and 12 weeks

  2. Change in Dynamic Cerebral Autoregulation

    Dynamic cerebral autoregulation will be assessed using transcranial Doppler ultrasound during controlled oscillatory lower-body negative pressure. Projection pursuit regression analysis will be applied to characterize the nonlinear relationship between arterial blood pressure and cerebral blood flow velocity. The primary autoregulatory metrics will include the active autoregulatory range (mmHg), defined as the arterial pressure range over which cerebral blood flow velocity remains relatively stable, as well as the slope of the active autoregulatory range, the rising slope, and the falling slope (all expressed in cm/s/mmHg). A wider active autoregulatory range and flatter slopes indicate more effective autoregulatory buffering capacity.

    Time frame: Baseline and 12 weeks

  3. Change in Cerebrovascular Reactivity

    Cerebrovascular reactivity will be assessed using transcranial Doppler ultrasound during a standardized carbon dioxide rebreathing protocol. Reactivity will be quantified as the slope of the cerebral blood flow velocity response to changes in end-tidal carbon dioxide. The primary metric will be expressed as cm/s/mmHg or percent change per mmHg. Steeper slopes indicate improved cerebrovascular responsiveness.

    Time frame: Baseline and 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for May 2028, 17 months later.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 17 months is below that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Dec 2026, on Oct 14, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2026
First posted
Mar 3, 2026
StartEst.
Dec 2026was Jun 2026
Primary completionEst.
May 2028
CompletionEst.
May 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Dec 2026
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Start date Jun 2026→Dec 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07444554
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Dec 2026 (estimated)
Primary completion
May 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Stacey E Aaron, PhD
Contact
seaaron@uic.edu
312-355-7220

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion